110505-75-4

Basic information

• Product Name: PARA-TOPOLIN RIBOSIDE 99% (HPLC)
• Synonyms: PARA-TOPOLIN RIBOSIDE 99% (HPLC);N-[(4-Hydroxyphenyl)methyl]adenosine;N6-(4-Hydroxybenzyl)adenosine
• CAS NO: 110505-75-4
• Molecular Formula: C17H19N5O5
• Molecular Weight: 373.36326
• Mol File: 110505-75-4.mol
• Article Data: 9

Chemical Properties

• Melting Point: 201-204 °C(Solv: methanol (67-56-1); chloroform (67-66-3))
• Boiling Point: 753.2±70.0 °C(Predicted)
• Appearance: /
• Density: 1.71
• Storage Temp.: Hygroscopic, Refrigerator, under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly, Sonicated)
• PKA: 9.72±0.15(Predicted)
• CAS DataBase Reference: PARA-TOPOLIN RIBOSIDE 99% (HPLC)(CAS DataBase Reference)
• NIST Chemistry Reference: PARA-TOPOLIN RIBOSIDE 99% (HPLC)(110505-75-4)
• EPA Substance Registry System: PARA-TOPOLIN RIBOSIDE 99% (HPLC)(110505-75-4)

Safety Data

• Hazardous Substances Data: 110505-75-4(Hazardous Substances Data)

Usage

Uses

N6-(4-Hydroxybenzyl)adenosine is am endogenous compound extracted from G. elata for research interest for its potential sedative and hypnotic activity, as well as a neuroprotective and therapeutic agent for preventing and treating neurodegenerative disease.

Upstream product

• 80054-30-4 6-(4-hydroxybenzylamino)purine 
• 22164-16-5 7-methylguanosine 
• 2004-06-0 6-Chloropurine riboside 
• 696-60-6 4-aminomethylphenol 
• 123-08-0 4-hydroxy-benzaldehyde 
• 699-06-9 4-hydroxybenzaldehyde oxime 
• 1004-23-5 4-hydroxy-benzylamine hydrochloride 

Downstream Products

• 1375410-34-6 N6-(4-hydroxybenzyl)-2’,3’-O-isopropylidene-adenosine 

Relevant articles and documents

Synthesis of [15N4] purine labeled cytokinin glycosides derived from zeatins and topolins with 9-β-d, 7-β-d-glucopyranosyl, or 9-β-d-ribofuranosyl group

Synthesis of [15N4] purine labeled cytokinine glycosides derived from zeatins and topolins containing a 9-β-d, 7-β-d-glucopyranosyl, or 9-β-d-ribofuranosyl group is described. These N6-substituted adenine derivatives are i

Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases

The present invention provides therapeutic agents for preventing and treating neurodegenerative diseases. These agents synergistically target both the adenosine A2A receptor (A2AR) and the equilibrative nucleoside transporter 1 (ENT1

N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF

The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.